What does International Stem Cell CORP (ISCO) do?

International Stem Cell CORP (ISCO) is a publicly traded company in the Healthcare sector.

What sector does ISCO operate in?

International Stem Cell CORP operates in the Healthcare, specifically within the Pharmaceuticals industry. AlphaOS tracks cycle stage, supply-chain relationships, and investment intelligence for companies across all sectors.

Where can I find ISCO earnings analysis?

AlphaOS publishes an earnings intelligence page for International Stem Cell CORP (ISCO) covering results, guidance context, and AI-assisted analysis. See /stocks/ISCO/earnings. Content is for research and education — not investment advice.

Coverage building

ISCO has basic price and filing data (45% intelligence coverage), but earnings analysis, financial metrics, and proprietary signals are still building. Explore a peer with deeper coverage below.

Deeper coverage nearby

Intelligence coverage: 45%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

ISCO

International Stem Cell CORP

Healthcare · Pharmaceuticals

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

International Stem Cell CORP shows stable business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +9% YoY in Q2 FY2026.

TrajectoryStable

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Revenue +9% YoY in Q2 FY2026

Pipeline evidence · 0d ago

ISCO's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on ISCO.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full ISCO earnings analysis

Reported figures for International Stem Cell CORP — research only, not investment advice.

Revenue YoY: +9.4%
EPS YoY: -200.0%

Latest Intelligence

Updated September 29, 2026

What happened recently for International Stem Cell CORP (ISCO) — events, not interpretation.

Event: Reported Q2 2026 revenue +9% YoY.
Source: Q2 2026 earnings

Research & analysis only — not investment advice.

Building company intelligence…

International Stem Cell CORP (ISCO)

Healthcare · Pharmaceuticals

Investment Snapshot above is the primary AlphaOS analysis for International Stem Cell CORP — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: Pharmaceuticals
Revenue:: $7.46M

ISCO earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow International Stem Cell CORP through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Related & Connected

Connected companies and research pages from the AlphaOS knowledge graph.